Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/5/2020
SIETES contiene 93010 citas

 
 
 1 a 20 de 1207 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, et al.. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:29 de abril. [Ref.ID 103630]
2. Cita con resumen
Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F-X, Nicastri E, Oda R, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020:10 de abril. [Ref.ID 103581]
4. Cita con resumen
Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020:17 de febrero. [Ref.ID 103537]
5. Cita con resumen
McEvoy JB, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, Ballantyne CM, Coresh J, Selvin E. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:28 de enero. [Ref.ID 103512]
6. Cita con resumen
Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLOS Medicine 0:9 de diciembre. [Ref.ID 103502]
7.Enlace a cita original Cita con resumen
Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jeong S, Tchoe HJ, Shin JY. All-cause mortality associated with tramadol use: a case-crossover study. Drug Saf 2019;42:junio. [Ref.ID 103119]
10.Enlace a cita original Cita con resumen
Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. JAMA Surgery 2019:24 de abril. [Ref.ID 103091]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
12.Enlace a cita original Cita con resumen
Ueda P, Svanström H, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:14 de noviembre. [Ref.ID 102869]
13.Enlace a cita original Cita con resumen
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018:9 de noviembre. [Ref.ID 102850]
14. Cita con resumen
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Richard Hobbs FD, McManus RJ. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 2018:29 de octubre. [Ref.ID 102837]
15.Enlace a cita original Cita con resumen
Kitchlu A, Shapiro J, Amir E, Garg AX, Kim J, Wald R, Harel Z. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA 2018;319:19 de junio. [Ref.ID 102790]
16.Enlace a cita original Cita con resumen
Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]
19. Cita con resumen
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 2017;167:845-54. [Ref.ID 102196]
20. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
Seleccionar todas
 
 1 a 20 de 1207 siguiente >>